Grannum Sant

Mar 21, 2018

Exosome Diagnostics has appointed Grannum Sant as its head of medical affairs. Sant holds an appointment as Professor of Urology at Tufts University, where he has spent more than two decades. He has also served various leadership positions in research and professional societies, including a term as President of the New England Section of the American Urological Association.

Outside of academia, Sant worked as a pharma medical affairs and clinical development executive, serving as a vice president of medical affairs at both Sanofi-Aventis US, and at Genzyme. Most recently he was the medical affairs lead for OPKO Health.

More Like This

Aug 17, 2018

Michelle Griffin

HTG Molecular Diagnostics has appointed Michelle Griffin to its board of directors. Griffin currently serves as a board member and chair of the audit committee for Acer Therapeutics. She has previously served as a board member and as audit committee chair for multiple firms since 2016, including PhaseRx, OncoGenex Pharmaceuticals, and Sonus Pharmaceuticals. In addition, Griffin has served in executive roles at OncoGenex, Trubion Pharmaceuticals, Dendreon, and Corixa over the past two decades.

Aug 16, 2018

Jeffrey Henderson

Becton Dickinson has elected Jeffrey Henderson to its board of directors. Henderson is the non-executive chairman of the board of Qualcomm, serves on the boards of FibroGen and Halozyme Therapeutics, and is an advisory director to Berkshire Partners. He previously served as CFO of Cardinal Health for nearly 10 years and has also held positions at Eli Lilly and General Motors.

Aug 14, 2018

Christopher Bernard, Chris Emery

Curetis announced that Christopher Bernard has resigned as CEO and president of Curetis USA, as well as from the firm's management board, effective Aug. 31. The company has appointed Chris Emery to replace him, effective Sept. 1.


Bernard joined Curetis USA as CEO and president in July 2016 and had served on Curetis NV's management board since June 2018.

Emery has more than 20 years of commercial experience in the diagnostic and pharmaceutical industries. Prior to Curetis, Emery served as chief commercial officer of North America for Menarini Silicon Biosystems, where he directed US sales and business development activities for the DepArray Nxt molecular device and integrated the CellSearch Circulating Tumor Cell test. He has also served as general manager for Abbott's PersonalizeDx cancer diagnostics laboratory division and has held senior level management roles at CombiMatrix, Response Genetics, and US Labs.

Aug 09, 2018

Albert Parker

OncoCyte has appointed Albert Parker as its chief operating officer. According to the company, Parker is an attorney and executive with more than 25 years of pharmaceutical, biotech, and healthcare experience. Prior to joining OncoCyte, Parker served as the managing shareholder of GC Legal Advisors, where he represented and advised public and privately held companies, primarily in the life sciences industry. Among other prior roles, Parker has also served as executive VP, general counsel, and corporate secretary at Sunovion Pharmaceuticals, senior VP and chief counsel for Wyeth Pharmaceuticals, and partner at Schnader Harrison Segal & Lewis.

Aug 09, 2018

Kathleen LaPorte

Precipio has appointed Kathleen LaPorte to its board as an independent member. She will replace Michael Allen Luther, who first served on the board of Transgenomic starting in 2014 and remained on it after that firm merged with Precipio.  

LaPorte was a general partner with Sprout Group from 1993 to 2004 and was a founder of New Leaf Venture Partners. She is also a cofounder of Health Tech Capital and was CEO of immuno-oncology diagnostic company Nodality. 

Aug 09, 2018

Hal Barron, Hans Bishop

Grail has appointed Hal Barron and Hans Bishop to its board. Barron is the CSO and president of R&D at GlaxoSmithKline. Prior to that, he served as president of R&D at Calico. He has also held management positions at Roche Pharmaceuticals and Genentech and is associate adjunct professor of epidemiology and biostatistics at the University of California, San Francisco. 

Bishop founded Juno Therapeutics in 2013 and was the firm's president and CEO until this past March when it was acquired by Celgene. He previously served as executive-in-residence at Warburg Pincus and is currently on the boards of Agilent Technologies and Celgene.

Aug 08, 2018

Colin Albert

Genomiqa announced today that it has appointed Colin Albert as its new CEO. Albert previously held the roles of commercial head and regional general manager of the Asia-Pacific region for Roche Foundation Medicine. Prior to those roles, he served as VP of business effectiveness and strategy at Shanghai Roche Pharmaceuticals.

Aug 07, 2018

David Macdonald

First Light Biosciences has appointed David Macdonald its president, CEO, and board member. He was most recently CEO of Agendia, and before that was a division president, COO and vice president at Quest Diagnostics. 

Aug 06, 2018

Mitchell Nelles

CareDx Chief Operating Officer Mitchell Nelles told the company on July 31 that he intends to retire, effective Sept. 28, according to a document filed with the US Securities Exchange Commission. Nelles joined CareDx in 2007, when it was called XDx, as VP of R&D. Prior to that, Nelles served as VP of North American R&D at BioMérieux.

Aug 02, 2018

Steve McPhail

Fluidigm Chief Operating Officer Steve McPhail will retire in early 2019, CEO Chris Linthwaite said on a conference call discussing Fluidigm's second quarter earnings. McPhail is retiring to focus on family and his involvement with Improve Care Now, a non-profit dedicated to improving quality of care for children with Crohn's disease and inflammatory bowel disease. McPhail serves on the board of directors for the non-profit, as well as the board of directors of the North Carolina Children's Hospital. He has served as COO at Fluidigm since August 2016. He also previously served as president and CEO of Expression Analysis.

Aug 02, 2018

Eric Stawiski

Eric Stawiski has been appointed vice president of bioinformatics at MedGenome. He is tasked with scaling up the company's bioinformatics services and building new products and IP. He was previously at Genentech where he was a group leader for a team focused on analyzing RNA-seq, exome, and copy number data to identify potential driver genes and drug targets in cancers, as well as evaluating new sequencing technologies. 

Aug 02, 2018

John Clarkson

Dubai-based genomics firm Agiomix has appointed John Clarkson as chairman. Clarkson was previously founder and commercial director of Molecular Sensing, a rapid DNA analysis company that was acquired by Osmetech (now GenMark Dx). Clarkson was also founding CEO of Atlas Genetics, and remains a non-executive director there.

Jul 31, 2018

Didier Hirsch, Robert McMahon, Karleen Oberton

Agilent Technologies said its senior VP and CFO Didier Hirsch will retire, effective Oct 31. The company has appointed Robert McMahon, currently CFO of Hologic, as his successor. McMahon will join Agilent on Aug. 3 as senior VP and will become CFO on Sept. 1 when Hirsch steps down from that post. Hirsch will continue as an active member of the executive staff until his retirement date at the end of the fiscal year and will work with McMahon to ensure a smooth transition.

Hirsch has served as Agilent's CFO since 2010. Before that, he had oversight of the corporate controllership and tax functions. He joined Agilent in 1999 as VP of treasury and investor relations. He also held various international finance positions at HP from 1989 until joining Agilent.
McMahon has served as Hologic's CFO since 2014. Prior to that, he spent 20 years with Johnson & Johnson, most recently as worldwide VP of finance and business development for Ortho Clinical Diagnostics. He also held a variety of financial leadership positions within Johnson & Johnson after joining the company in 1993.

Separately, Hologic said it would promote its current Chief Accounting Officer Karleen Oberton to replace McMahon as CFO. She joined Hologic in 2006 as corporate controller and was promoted to her current position in 2015. Prior to that, Oberton served as senior corporate controller for Immunogen, and as a senior audit manager for both Ernst Young and Arthur Andersen.

Jul 31, 2018

Rishi Kacker, Alexander Ford, Eric Evans, Lloyd Sanders

As part of Myriad Genetics' integration with recently acquired firm Counsyl, the company announced a number of personnel changes. Rishi Kacker, formerly Counsyl's senior VP of technology, will become Myriad's new chief technology officer. Alexander Ford, previously president of Myriad Genetic Laboratories, will be president of the company's women's health business unit, while Eric Evans, Counsyl's chief scientific officer, will now serve as the chief scientific officer of the women's health unit. Lastly, Lloyd Sanders, previously general manager of the oncology segment, will be president of Myriad's oncology business unit.

Jul 31, 2018

Markus Schunk

Definiens has announced that it appointed Markus Schunk as COO, effective Sept. 15, 2018. Prior to Definiens, Schunk was CEO and board chairman at Holtzbrinck Digital. 

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.